Abraxane Cost-Benefit Data Could Support Price Premium Over Taxol, Taxotere
This article was originally published in The Pink Sheet Daily
Executive Summary
American Pharmaceutical Partners plans to begin shipping Abraxane (nanoparticle albumin-bound paclitaxel) within 45 days. Based on data presented at the American Society of Clinical Oncology meeting, Abraxane demonstrated a cost-benefit to Bristol's Taxol and Aventis' Taxotere for treatment of breast cancer.